Table 5.

Cumulative incidence (95% CI) for developing a SPM among patients with BNHL subtypes

Year	DLBCL	CLL/SLL	FL	MCL	MZL	WM
1	0.02 (0.02-0.02)	0.02 (0.01-0.03)	0.01 (0.01-0.02)	0.02 (0.00-0.03)	0.02 (0.02-0.02)	0.01 (0.00-0.02)
3	0.08 (0.07-0.08)	0.08 (0.06-0.10)	0.06 (0.04-0.07)	0.10 (0.05-0.14)	0.07 (0.06-0.08)	0.06 (0.01-0.10)
5	0.11 (0.10-0.12)	0.15 (0.12-0.18)	0.09 (0.07-0.11)	0.12 (0.06-0.17)	0.12 (0.10-0.14)	0.07 (0.02-0.13)

CI, confidence interval; SPM, second primary malignancy; BNHL, B-cell non-Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; CLL/SLL, chronic lymphocytic and small lymphocytic lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; WM, Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma.